1. Home
  2. CRAI vs ESPR Comparison

CRAI vs ESPR Comparison

Compare CRAI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRA International Inc.

CRAI

CRA International Inc.

HOLD

Current Price

$149.08

Market Cap

898.0M

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.14

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRAI
ESPR
Founded
1965
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.0M
731.9M
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
CRAI
ESPR
Price
$149.08
$3.14
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$245.00
$8.75
AVG Volume (30 Days)
118.2K
9.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
1.48%
N/A
EPS Growth
20.77
60.71
EPS
8.14
N/A
Revenue
$751,583,000.00
$403,135,000.00
Revenue This Year
$7.82
N/A
Revenue Next Year
$5.14
$12.81
P/E Ratio
$18.24
N/A
Revenue Growth
9.33
21.31
52 Week Low
$132.17
$0.95
52 Week High
$227.29
$4.18

Technical Indicators

Market Signals
Indicator
CRAI
ESPR
Relative Strength Index (RSI) 51.19 68.83
Support Level $142.53 $3.11
Resistance Level $166.99 $3.18
Average True Range (ATR) 5.87 0.01
MACD 0.93 -0.03
Stochastic Oscillator 81.65 66.67

Price Performance

Historical Comparison
CRAI
ESPR

About CRAI CRA International Inc.

CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: